hepatitis c

In a lengthy column

There are very few issues as complicated and controversial as those i

In terms of public perception, drug companies rank in the gen

It is rare when a single drug entirely revolutionizes the tre

In Forbes, Dr. Josh Bloom, American Council on Science and Health Director of Chemical and Pharmaceutical Sciences, and Dr. Henry I.

Catch the latest news on concerns regarding Gilead's $84,000 hepatitis C treatment drug Sovaldi, the declining sales of traditional cigarettes, and why prior authorization could be hurting the health care system

There are now multiple ongoing discussions about Sovaldi, Gilead s

The recent approval and marketing of Gilead s hepatitis-C drug, Sovaldi, has spurred a revolt against expensive